Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 13.65% is 25% below its 5-year average of 18.12%, near the low end of its 5-year range (13.65%–43.03%).
As of the fiscal period ended Tuesday, June 30, 2026. 4.97% below its 12-month average of 14.36%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation.
RETURN ON EQUITY (ROE)
13.65%
RETURN ON EQUITY (ROE) AVG TTM
14.36%
RETURN ON EQUITY (ROE) AVG 3Y
14.91%
RETURN ON EQUITY (ROE) AVG 5Y
18.12%
RETURN ON EQUITY (ROE) AVG 10Y
20.83%
RETURN ON EQUITY (ROE) AVG 15Y
20.88%
RETURN ON EQUITY (ROE) AVG 20Y
9.11%
CURRENT VS TTM AVG
-4.97%
CURRENT VS 3Y AVG
-8.44%
CURRENT VS 5Y AVG
-24.66%
CURRENT VS 10Y AVG
-34.48%
CURRENT VS 15Y AVG
-34.62%
CURRENT VS 20Y AVG
+49.88%
SECTOR MEDIAN · HEALTHCARE
13.25%
median of 83 covered companies
CURRENT VS SECTOR MEDIAN
+3.02%
vs the sector median at left
Regeneron Pharmaceuticals, Inc.
Market Cap
$83.48B
Return on Equity (ROE)
13.65%
TTM Avg
14.36%
3Y Avg
14.91%
5Y Avg
18.12%
Market Cap
$87.04B
Return on Equity (ROE)
N/A
TTM Avg
-171.53%
3Y Avg
-210.62%
5Y Avg
-155.29%
Market Cap
$87.17B
Return on Equity (ROE)
11.06%
TTM Avg
13.69%
3Y Avg
14.71%
5Y Avg
14.93%
Market Cap
$72.89B
Return on Equity (ROE)
15.05%
TTM Avg
11.32%
3Y Avg
12.19%
5Y Avg
12.83%
Market Cap
$66.86B
Return on Equity (ROE)
14.71%
TTM Avg
10.21%
3Y Avg
8.16%
5Y Avg
6.40%
Market Cap
$63.17B
Return on Equity (ROE)
86.03%
TTM Avg
168.34%
3Y Avg
-32.99%
5Y Avg
148.52%
Market Cap
$104.10B
Return on Equity (ROE)
N/A
TTM Avg
-189.06%
3Y Avg
-180.53%
5Y Avg
3473.86%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. (REGN) | $83.48B | 13.65% | 14.36% | 14.91% | 18.12% |
| HCA Healthcare, Inc. (HCA)vs › | $87.04B | N/A | -171.53% | -210.62% | -155.29% |
| Elevance Health Inc. (ELV)vs › | $87.17B | 11.06% | 13.69% | 14.71% | 14.93% |
| Cigna Corporation (CI)vs › | $72.89B | 15.05% | 11.32% | 12.19% | 12.83% |
| GSK plc (GSK)vs › | $97.25B | 27.67% | 26.90% | 55.97% | 45.70% |
| Boston Scientific Corporation (BSX)vs › | $66.86B | 14.71% | 10.21% | 8.16% | 6.40% |
| Sanofi (SNY)vs › | $103.62B | 5.82% | 9.06% | 9.15% | 10.86% |
| Cencora, Inc. (COR)vs › | $63.17B | 86.03% | 168.34% | -32.99% | 148.52% |
| McKesson Corporation (MCK)vs › | $104.10B | N/A | -189.06% | -180.53% | 3473.86% |
| Stryker Corporation (SYK)vs › | $105.97B | 15.55% | 14.50% | 15.05% | 14.30% |
ROE
13.7%
ROA
10.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 13.65% |
| 2026-03-31 | 14.08% |
| 2025-12-31 | 14.41% |
| 2025-09-30 | 14.79% |
| 2025-06-30 | 14.89% |
| 2025-03-31 | 15.31% |
| 2024-12-31 | 15.03% |
| 2024-09-30 | 15.87% |
| 2024-06-30 | 15.32% |
| 2024-03-31 | 14.29% |
| 2023-12-31 | 15.22% |
| 2023-09-30 | 16.03% |
| 2023-06-30 | 17.90% |
| 2023-03-31 | 17.80% |
| 2022-12-31 | 19.14% |
| 2022-09-30 | 25.05% |
| 2022-06-30 | 27.49% |
| 2022-03-31 | 39.84% |
| 2021-12-31 | 43.03% |
| 2021-09-30 | 40.53% |
| 2021-06-30 | 41.02% |
| 2021-03-31 | 33.43% |
| 2020-12-31 | 31.86% |
| 2020-09-30 | 31.17% |
| 2020-06-30 | 32.94% |
| 2020-03-31 | 18.79% |
| 2019-12-31 | 19.08% |
| 2019-09-30 | 20.41% |
| 2019-06-30 | 21.21% |
| 2019-03-31 | 25.70% |
| 2018-12-31 | 27.91% |
| 2018-09-30 | 22.85% |
| 2018-06-30 | 22.14% |
| 2018-03-31 | 21.74% |
| 2017-12-31 | 19.51% |
| 2017-09-30 | 21.12% |
| 2017-06-30 | 20.91% |
| 2017-03-31 | 19.79% |
| 2016-12-31 | 19.78% |
| 2016-09-30 | 17.41% |
| 2016-06-30 | 17.84% |
| 2016-03-31 | 19.28% |
| 2015-12-31 | 17.40% |
| 2015-09-30 | 17.93% |
| 2015-06-30 | 13.80% |
| 2015-03-31 | 12.07% |
| 2014-12-31 | 13.69% |
| 2014-09-30 | 13.12% |
| 2014-06-30 | 16.73% |
| 2014-03-31 | 17.68% |
| 2013-12-31 | 21.74% |
| 2013-09-30 | 47.21% |
| 2013-06-30 | 56.79% |
| 2013-03-31 | 59.55% |
| 2012-12-31 | 60.24% |
| 2012-09-30 | 28.09% |
| 2012-06-30 | -4.61% |
| 2012-03-31 | -33.07% |
| 2011-12-31 | -45.65% |
| 2011-09-30 | -42.71% |
| 2011-06-30 | -32.30% |
| 2011-03-31 | -22.66% |
| 2010-12-31 | -19.79% |
| 2010-09-30 | -36.30% |
| 2010-06-30 | -25.19% |
| 2010-03-31 | -21.48% |
| 2009-12-31 | -17.62% |
| 2009-09-30 | -15.38% |
| 2009-06-30 | -20.72% |
| 2009-03-31 | -21.59% |
| 2008-12-31 | -19.75% |
| 2008-09-30 | -14.71% |
| 2008-06-30 | -17.51% |
| 2008-03-31 | -18.95% |
| 2007-12-31 | -22.94% |
| 2007-09-30 | -81.57% |
| 2007-06-30 | -64.17% |
| 2007-03-31 | -56.88% |
| 2006-12-31 | -47.24% |
| 2006-09-30 | -161.73% |
| 2006-06-30 | -129.26% |
| 2006-03-31 | -109.17% |
| 2005-12-31 | -83.72% |
| 2005-09-30 | -46.18% |
| 2005-06-30 | -23.87% |
| 2005-03-31 | -14.51% |
| 2004-12-31 | 22.84% |
| 2004-09-30 | 10.92% |
| 2004-06-30 | 1.69% |
| 2004-03-31 | -5.38% |
| 2003-12-31 | -76.74% |
| 2003-09-30 | -78.06% |
| 2003-06-30 | -92.39% |
